JP2015504430A - Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法 - Google Patents

Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法 Download PDF

Info

Publication number
JP2015504430A
JP2015504430A JP2014542299A JP2014542299A JP2015504430A JP 2015504430 A JP2015504430 A JP 2015504430A JP 2014542299 A JP2014542299 A JP 2014542299A JP 2014542299 A JP2014542299 A JP 2014542299A JP 2015504430 A JP2015504430 A JP 2015504430A
Authority
JP
Japan
Prior art keywords
psa
allele
patient
antagonist
responsive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014542299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504430A5 (https=
Inventor
ワン，イン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2015504430A publication Critical patent/JP2015504430A/ja
Publication of JP2015504430A5 publication Critical patent/JP2015504430A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rehabilitation Therapy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
JP2014542299A 2011-11-21 2012-06-07 Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法 Pending JP2015504430A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IQ3702011 2011-11-21
IQ370/2011 2011-11-21
US201261624564P 2012-04-16 2012-04-16
US61/624,564 2012-04-16
PCT/US2012/041310 WO2013077907A1 (en) 2011-11-21 2012-06-07 Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles

Publications (2)

Publication Number Publication Date
JP2015504430A true JP2015504430A (ja) 2015-02-12
JP2015504430A5 JP2015504430A5 (https=) 2015-07-23

Family

ID=48470189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014542299A Pending JP2015504430A (ja) 2011-11-21 2012-06-07 Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法

Country Status (12)

Country Link
US (1) US20150064193A1 (https=)
EP (1) EP2783014A1 (https=)
JP (1) JP2015504430A (https=)
KR (1) KR20140097178A (https=)
CN (1) CN104011223A (https=)
AR (1) AR086907A1 (https=)
AU (1) AU2012341081B2 (https=)
BR (1) BR112014012101A2 (https=)
CA (1) CA2856252A1 (https=)
MX (1) MX2014006158A (https=)
RU (1) RU2014125071A (https=)
WO (1) WO2013077907A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
CN103154031A (zh) 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
BR112013011176A2 (pt) 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US10220076B2 (en) 2014-05-15 2019-03-05 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising glucose regulating proteins
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CN115957326A (zh) * 2014-09-10 2023-04-14 诺华股份有限公司 使用il-17拮抗剂抑制银屑病关节炎患者的结构损伤进展
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
TW201639596A (zh) * 2015-01-24 2016-11-16 艾伯維有限公司 用於治療牛皮癬性關節炎之組合物及方法
CN116059350A (zh) 2015-10-27 2023-05-05 Ucb生物制药有限责任公司 使用抗-il-17a/f抗体的治疗方法
IL283192B2 (en) * 2018-11-20 2025-10-01 Janssen Biotech Inc A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
MA56124A (fr) * 2019-06-04 2022-04-13 Janssen Biotech Inc Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23
TW202126329A (zh) * 2019-09-20 2021-07-16 瑞士商諾華公司 使用白細胞介素－１７（ｉｌ－１７）拮抗劑治療自體免疫性疾病之方法
EP4305062A1 (en) * 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
IL305802A (en) * 2021-03-12 2023-11-01 Janssen Biotech Inc A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody
CN114427001A (zh) * 2022-01-29 2022-05-03 中日友好医院(中日友好临床医学研究所) 基于78个snp位点评估阿达木单抗治疗银屑病有效性的试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507988A (ja) * 2004-08-05 2008-03-21 ノバルティス アクチエンゲゼルシャフト Ｉｌ−１７拮抗性抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP1963368B3 (en) 2005-12-13 2020-06-10 Eli Lilly And Company Anti-il-17 antibodies
BRPI0706788A2 (pt) 2006-01-31 2011-04-05 Novartis Ag anticorpos antagonistas il-17
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US20100239590A1 (en) * 2007-06-20 2010-09-23 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
NZ591484A (en) 2008-09-29 2012-09-28 Roche Glycart Ag Antibodies against human il 17 and uses thereof
AU2010276665A1 (en) * 2009-07-28 2012-02-23 Janssen Biotech, Inc. Serum markers predicting clinical response to anti-TNFalpha antibodies in patients with psoriatic arthritis
CN103154031A (zh) * 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
TW201307845A (zh) * 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507988A (ja) * 2004-08-05 2008-03-21 ノバルティス アクチエンゲゼルシャフト Ｉｌ−１７拮抗性抗体

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6016009264; ＬＡＭＢＥＲＴ　Ｓ．　ｅｔ　ａｌ．: 'ＴＲＡＦ３ＩＰ２　ｃｏｕｐｌｅｓ　ＩＬ-１７　ｔｏ　ｔｈｅ　ｅｐｉｄｅｒｍａｌ　ｄｅｆｅｎｓｅ　ｒｅｓｐｏｎｓｅ' Ｊｏｕｒｎａｌ　ｏｆ　Ｉｎｖｅｓｔｉｇａｔｉｖｅ　Ｄｅｒｍａｔｏｌｏｇｙ Ｖｏｌ．１３１，　Ｓｕｐｐｌ．２, 201109, ｐ．Ｓ１９，　Ａｂｓｔｒａｃｔ　Ｎｏ．１１２ *
JPN6016009265; ＬＡＭＢＥＲＴ　Ｓ．　ｅｔ　ａｌ．: 'ＴＲＡＦ３ＩＰ２　ｃｏｕｐｌｅｓ　ＩＬ-１７　ｔｏ　ｔｈｅ　ｅｐｉｄｅｒｍａｌ　ｄｅｆｅｎｓｅ　ｒｅｓｐｏｎｓｅ' Ｊｏｕｒｎａｌ　ｏｆ　Ｉｎｖｅｓｔｉｇａｔｉｖｅ　Ｄｅｒｍａｔｏｌｏｇｙ Ｖｏｌ．１３１，　Ｓｕｐｐｌ．１, 201104, ｐ．Ｓ６，　Ａｂｓｔｒａｃｔ　Ｎｏ．０３４ *
JPN6016009266; ＶＥＬＩＣＨＫＯ　Ｓ．　ｅｔ　ａｌ．: 'Ｇｌｏｂａｌ　ｇｅｎｅ　ｅｘｐｒｅｓｓｉｏｎ　ａｎａｌｙｓｉｓ　ｏｆ　Ａｃｔ１'ｓ　ｅｆｆｅｃｔｓ　ｉｎ　ａｉｒｗａｙ　ｅｐｉｔｈｅｌｉａｌ　ｃｅｌｌｓ' Ｊｏｕｒｎａｌ　ｏｆ　Ｉｍｍｕｎｏｌｏｇｙ Ｖｏｌ．１８６，　ＭｅｅｔｉｎｇＡｂｓｔｒａｃｔｓ, 201104, Ａｂｓｔｒａｃｔ　Ｎｏ．１６１．１７ *
JPN6016009267; ＥＬＬＩＮＧＨＡＵＳ　Ｅ．　ｅｔ　ａｌ．: 'Ｇｅｎｏｍｅ-ｗｉｄｅ　ａｓｓｏｃｉａｔｉｏｎ　ｓｔｕｄｙ　ｉｄｅｎｔｉｆｉｅｓ　ａ　ｐｓｏｒｉａｓｉｓ　ｓｕｓｃｅｐｔｉｂｉｌｉｔｙ　ｌｏｃｕｓ　ａｔ　ＴＲＡＦ３ＩＰ２' Ｎａｔｕｒｅ　Ｇｅｎｅｔｉｃｓ Ｖｏｌ．４２，　Ｎｏ．１１, 2010, ｐ．９９１-５ *
JPN6016009268; ＧＬＡＤＭＡＮ　Ｄ．Ｄ．　ｅｔ　ａｌ．: 'ＨＬＡ-ＤＲＢ１＊０４　ａｌｌｅｌｅｓ　ｉｎ　ｐｓｏｒｉａｔｉｃ　ａｒｔｈｒｉｔｉｓ：　ｃｏｍｐａｒｉｓｏｎ　ｗｉｔｈ　ｒｈｅｕｍａｔｏｉｄ　ａｒｔｈｒｉｔｉｓ　ａｎｄ　ｈｅａｌｔｈｙ　ｃｏｎｔｒｏｌ' Ｈｕｍａｎ　Ｉｍｍｕｎｏｌｏｇｙ Ｖｏｌ．６２，　Ｎｏ．１１, 2001, ｐ．１２３９-４４ *
JPN6016009269; ＭＣＩＮＮＥＳ　Ｉ．　ｅｔ　ａｌ．: 'Ａｎｔｉ-ｉｎｔｅｒｌｅｕｋｉｎ　１７Ａ　ｍｏｎｏｃｌｏｎａｌ　ａｎｔｉｂｏｄｙ　ｓｅｃｕｋｉｎｕｍａｂ　ｒｅｄｕｃｅｓ　ｓｉｇｎｓ　ａｎｄ　ｓｙｍｐｔｏｍｓ　ｏｆ　ｐｓｏｒｉａｔｉｃ　ａｒｔｈｒｉｔ' Ａｒｔｈｒｉｔｉｓ　ａｎｄ　Ｒｈｅｕｍａｔｉｓｍ Ｖｏｌ．６３，　Ｓｕｐｐｌ．１０, 201110, Ａｂｓｔｒａｃｔ　Ｎｏ．７７９ *

Also Published As

Publication number Publication date
BR112014012101A2 (pt) 2019-09-24
AU2012341081B2 (en) 2015-06-04
CA2856252A1 (en) 2013-05-30
WO2013077907A1 (en) 2013-05-30
AU2012341081A1 (en) 2014-05-29
KR20140097178A (ko) 2014-08-06
MX2014006158A (es) 2014-06-19
RU2014125071A (ru) 2015-12-27
AR086907A1 (es) 2014-01-29
EP2783014A1 (en) 2014-10-01
US20150064193A1 (en) 2015-03-05
CN104011223A (zh) 2014-08-27

Similar Documents

Publication Publication Date Title
AU2012341081B2 (en) Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
CN106536754B (zh) 用il-13拮抗剂选择性治疗哮喘的方法
US20150125462A1 (en) Methods of treating ankylosing spondylitis using il-17 antagonists
US11725246B2 (en) Methods of treating ophthalmic disorders
TW201307845A (zh) 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
EP2531613A2 (en) Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
WO2014155278A2 (en) Methods of treating autoimmune diseases using il-17 antagonists
TW201343176A (zh) 使用ｉｌ－１７拮抗劑治療乾癬性關節炎之方法
CN109311976A (zh) 使用TNFα拮抗剂治疗干眼症的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161025